Remote management of hidradenitis suppurativa in a pandemic era of COVID-19

Int J Dermatol. 2020 Sep;59(9):e318-e320. doi: 10.1111/ijd.15022. Epub 2020 Jun 23.

Authors

Na-Young C Kang¹, Jennifer Hsiao², Vivian Shi³, Haley B Naik⁴, Michelle A Lowes⁵, Afsaneh Alavi^{6

7}

Affiliations

¹ Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
² Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
³ Division of Dermatology, Department of Medicine, University of Arizona, Tucson, AZ, USA.
⁴ Department of Dermatology, University of California, San Francisco, CA, USA.
⁵ Rockefeller University, New York, NY, USA.
⁶ Division of Dermatology, Women's College Hospital, Toronto, ON, Canada.
⁷ Department of Dermatology, University of Toronto, Toronto, ON, Canada.

No abstract available

Publication types

Letter

MeSH terms

Betacoronavirus / immunology
Betacoronavirus / pathogenicity
Biological Products / adverse effects
COVID-19
Coronavirus Infections / epidemiology
Coronavirus Infections / immunology
Coronavirus Infections / prevention & control*
Coronavirus Infections / transmission
Dermatology / methods*
Dermatology / standards
Hidradenitis Suppurativa / diagnosis
Hidradenitis Suppurativa / drug therapy*
Hidradenitis Suppurativa / immunology
Humans
Immunocompromised Host
Infection Control / standards*
Pandemics / prevention & control*
Pneumonia, Viral / epidemiology
Pneumonia, Viral / immunology
Pneumonia, Viral / prevention & control*
Pneumonia, Viral / transmission
SARS-CoV-2
Symptom Flare Up
Telemedicine / methods*
Telemedicine / standards

Substances

Biological Products

Grants and funding

K23 AR074531/AR/NIAMS NIH HHS/United States